Literature DB >> 28123573

Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347.

Hongwu Fan1, Guangyao Liu1, Changfu Zhao1, Xuefeng Li2, Xiaoyu Yang3.   

Abstract

Osteosarcoma is the most common primary bone tumor in children and adolescents, typically presenting with a poor prognosis. Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer. However, its role in osteosarcoma remains to be elucidated. The present study observed Oct4 was markedly increased in osteosarcoma cell lines and in human osteosarcoma tissue samples. Following Oct4 downregulation by small interfering RNA (siRNA) in osteosarcoma F5M2 cells, the cells exhibited significant decreases in proliferation and invasion ability, and an increase in cell apoptosis. Notably, downregulation of Oct4 decreased the expression of AK055347, a newly identified long noncoding RNA (lncRNA) in human tissues. The downregulation of AK055347 by siRNA resulted in a significant suppressive effect on proliferative and invasive ability, and promotion of cell apoptosis in osteosarcoma cells. Thus, the current study suggests Oct4 exerts a promoting effect in osteosarcoma, and identifies a novel lncRNA in osteosarcoma progression.

Entities:  

Keywords:  AK055347; Oct4; POU5F1; lncRNA; osteosarcoma

Year:  2016        PMID: 28123573      PMCID: PMC5244871          DOI: 10.3892/ol.2016.5400

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

1.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

2.  Transcriptional activation of OCT4 by the ETS transcription factor PEA3 in NCCIT human embryonic carcinoma cells.

Authors:  Sung-Won Park; Hyun-Jin Do; Woo Tae Ha; Mi-Hee Han; Keun-Hong Park; Hyuk Song; Nam-Hyung Kim; Jae-Hwan Kim
Journal:  FEBS Lett       Date:  2014-06-28       Impact factor: 4.124

3.  TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells.

Authors:  Yusheng Huang; Huanzi Dai; Qiao-Nan Guo
Journal:  Apoptosis       Date:  2012-08       Impact factor: 4.677

4.  MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.

Authors:  Yongqiang Dong; Guojun Liang; Bo Yuan; Chaoqun Yang; Rui Gao; Xuhui Zhou
Journal:  Tumour Biol       Date:  2014-11-28

5.  Oct4 is expressed in human gliomas and promotes colony formation in glioma cells.

Authors:  Zhanhui Du; Deyong Jia; Shangming Liu; Fuwu Wang; Gang Li; Yanmin Zhang; Xinmin Cao; Eng-Ang Ling; Aijun Hao
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

6.  Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer.

Authors:  Esra Guzel; Omer F Karatas; Mehmet B Duz; Mustafa Solak; Michael Ittmann; Mustafa Ozen
Journal:  Prostate       Date:  2014-08-29       Impact factor: 4.104

7.  Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma.

Authors:  Alireza Shahryari; Mahmoud Reza Rafiee; Youssef Fouani; Nasrin Alipour Oliae; Nader Mansour Samaei; Mohammad Shafiee; Shahryar Semnani; Mohammad Vasei; Seyed Javad Mowla
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

8.  Comparative analysis of Oct4 in different histological subtypes of esophageal squamous cell carcinomas in different clinical conditions.

Authors:  Kim Vaiphei; Saroj Kant Sinha; Rakesh Kochhar
Journal:  Asian Pac J Cancer Prev       Date:  2014

9.  miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells.

Authors:  Jianghong Hu; Yue Fang; Yuan Cao; Rong Qin; Qiaoyun Chen
Journal:  Dig Dis Sci       Date:  2013-11-19       Impact factor: 3.199

10.  A novel long non-coding RNA, hypoxia-inducible factor-2α promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro.

Authors:  Yongcheng Wang; Jie Yao; Haoye Meng; Zhiguo Yu; Zhigang Wang; Xueling Yuan; Hong Chen; Aiyuan Wang
Journal:  Mol Med Rep       Date:  2014-12-01       Impact factor: 2.952

View more
  6 in total

1.  Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer.

Authors:  Qiuyan Guo; Junwei Wang; Yue Gao; Xin Li; Yangyang Hao; Shangwei Ning; Peng Wang
Journal:  Front Bioeng Biotechnol       Date:  2020-05-13

Review 2.  Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.

Authors:  Camille Jubelin; Javier Muñoz-Garcia; Denis Cochonneau; Emilie Moranton; Marie-Françoise Heymann; Dominique Heymann
Journal:  Cancer Drug Resist       Date:  2022-02-16

3.  Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway.

Authors:  Xin Zi; Guoqiang Zhang; Shichao Qiu
Journal:  Epigenetics       Date:  2021-04-02       Impact factor: 4.528

4.  The Na+/K+ ATPase Inhibitor Ouabain Attenuates Stemness and Chemoresistance of Osteosarcoma Cells.

Authors:  Weixiong Guo; Bo Wei; Tingting Cheng; Xiaotao Xu; Feiling Ruan; Min Xiang
Journal:  Med Sci Monit       Date:  2019-12-11

5.  NDUFA4L2 is associated with clear cell renal cell carcinoma malignancy and is regulated by ELK1.

Authors:  Lei Wang; Zhiqiang Peng; Kaizhen Wang; Yijun Qi; Ying Yang; Yue Zhang; Xinyuan An; Shudong Luo; Junfang Zheng
Journal:  PeerJ       Date:  2017-11-17       Impact factor: 2.984

6.  A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.

Authors:  Zedan Zhang; Yanlin Tang; Yanjun Liu; Hongkai Zhuang; Enyu Lin; Lu Xie; Xiaoqiang Feng; Kaiwen Tian; Jiayi Zeng; Jiumin Liu; Yuming Yu
Journal:  J Immunol Res       Date:  2021-06-28       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.